Idarubicin Completed Phase 1 Trials for Drug/Agent Toxicity by Tissue/Organ / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02652871LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00003268Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00093483Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
NCT00107523Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
NCT00505700VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia